Clinical trials: Obesity or Overweight
Overweight and Obesity, Cardiovascular Diseases
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.
- Conditions
- Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2
- Trial name
- SCOOP-RNPC (NCT05857319)
- Testing
- Nutritional Psycho-Behavioral Reeducation Program
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Groupe Éthique et Santé
Healthy
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
This study is open to healthy people and people with overweight or obesity. It has 2 parts. Part A is open to healthy men between 18 and 55 years of age.
- Trial name
- NCT06352437
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Type 2 Diabetes Mellitus (T2DM)
MagDI Italian Study
The objective of the MagDI Italy Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Conditions
- Obesity, Type 2 Diabetes Mellitus (T2DM), Anastomosis
- Trial name
- NCT06613711
- Testing
- Magnet System, DI Biofragmentable
- Where
- 4 sites in Italy
- Volunteers
- 27 people
- Sponsor
- GT Metabolic Solutions, Inc.
Healthy
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects
This is a single centre, phase I, randomized, double-blind, placebo-controlled, crossover, dose escalating study of P7435 using single and multiple doses, to be conducted in healthy male and female (Non child bearing) subjects…
- Trial name
- NCT01910571
- Testing
- P7435
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Obesity
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide.
- Trial name
- NCT06716307
- Testing
- CagriSema (cagrilintide B and semaglutide I), CagriSema A
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
This study is open to adults who are at least 18 years old and have presumed or confirmed NASH together with overweight or obesity and a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² and at least one…
- Trial name
- NCT06309992
- Testing
- Survodutide
- Where
- 37 sites in United States, Spain
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Healthy, Obesity
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity.
- Conditions
- Healthy, Obesity, Overweight
- Trial name
- NCT07232732
- Testing
- LY3549492
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
This study consists of two phases: Phase A and Phase B. Participants are being asked to participate in both phases. Phase A of this study is comparing two formulations of a study medicine called NNC0487-0111 for weight control in…
- Trial name
- NCT06478563
- Testing
- NNC0487-0111 (formulation D), NNC0487-0111 (formulation C)
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Blood Glucose Stability and Variability on Two Diets
This investigation will examine the effects of consuming a structured, portion-controlled, low-glycemic index diet (commercially available as the Nutrisystem-D program) on several indicators of glycemic stability and variability…
- Trial name
- NCT01443143
- Testing
- Portion-controlled diet, Usual Diet
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nutrisystem, Inc.
Overweight or Obesity
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
This Phase I, active-controlled, randomised trial will be conducted in 2 parts. Part I aims to confirm the PD equivalence of EMP22 and Xenical® based on percent fecal fat excretion at steady state.
- Trial name
- NCT06013163
- Testing
- Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical®
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Obesity, Genetic Obesity
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor…
- Trial name
- NCT05093634
- Testing
- Setmelanotide
- Where
- 56 sites in United States, Canada and 8 more
- Volunteers
- 296 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine
This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both.
- Trial name
- NCT06642571
- Testing
- NNC0519-0130 B, NNC0519-0130 C
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066…
- Trial name
- NCT03100058
- Testing
- LIK066
- Where
- 83 sites in United States, Austria and 5 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight and Obesity
Study of the Intestinal Microbiota During a Real Life Dietary Intervention in Subjects With Overweight or Obesity
Worldwide, 13% of the population had obesity in 2016 and overweight and obesity are recognized as the fifth leading risk factor for death (roughly 5 million deaths per year).
- Trial name
- GUTINSIDE (NCT04822948)
- Where
- France
- Volunteers
- 1,855 people
- Sponsor
- Integrative Phenomics
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07855133
- Testing
- Semaglutide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 6 (NCT03811574)
- Testing
- Semaglutide
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.
- Trial name
- NCT00785408
- Testing
- AC2307
- Where
- 18 sites in United States
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited